Search Results

Thank you to all participants in Dr. Terry Kenakin's educational initiative this fall!

At Dr. GPCR, we recognized this core problem.

Receptor 2 In Diabetic Retinopathy PhD Opportunity - Novel P2y Receptor Ligands For Drug Discovery Explore Dr

Explore Dr. GPCR Ecosystem

postdoctoral training at Boston Children’s Hospital and Harvard Medical School, he joined the lab of Dr

of Staff Postdoctoral Fellow, Biochemical And Cellular Pharmacology Project Leader, Biology Explore Dr

Receptor 2 In Diabetic Retinopathy PhD Opportunity - Novel P2y Receptor Ligands For Drug Discovery Explore Dr

Monthly AMAs  where you can challenge Dr. Kenakin with your own enzyme or GPCR interaction puzzles.

Applying Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders with Tim Dyer Addex Therapeutics "Tim Dyer is the Co-Founder and CEO of Addex Therapeutics, which is focusing on the

It's starting to look a lot like Christmas at Dr. GPCR!

Developing Nations If you reside and work in a developing country, complete this form for free access to Dr

live and work  in a developing country, please complete this form to enjoy complimentary access to Dr

Tim Dyer, CEO, Roger Mills, CMO and Robert Lütjens, Head of Discovery Biology, will provide a business

Explore Dr. GPCR Ecosystem

Developing Nations If you reside and work in a developing country, complete this form for free access to Dr

3D was used to predict subtype-selective ligands for dopamine receptors and adenosine receptors (He, Ben

strategic priorities, including pursuing additional collaborations across our portfolio,” said Tim Dyer

Explore Dr. GPCR Ecosystem

postdoctoral training, I joined one of the labs that participated in Latrophilins’ discovery, the lab of Dr

Dr. Rößler P, Mayer D, Tsai CJ, Veprintsev DB, Schertler GFX, Gossert AD.

which have an established role in chemokine gradients and oligomerization (Deshauer C et al. 2015; Dyer

.; Iyer, M. R.; Cinar, R.; Coffey, N.